{"id":568682,"date":"2021-10-12T17:52:02","date_gmt":"2021-10-12T17:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568682"},"modified":"2021-10-12T17:52:02","modified_gmt":"2021-10-12T17:52:02","slug":"opioid-overdose-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-purdue-pharma-orexo-quivivepharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/opioid-overdose-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-purdue-pharma-orexo-quivivepharma-and-others_568682.html","title":{"rendered":"Opioid Overdose Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies &#8211; Purdue Pharma, Orexo, Quivivepharma, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Opioid Overdose Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - Purdue Pharma, Orexo, Quivivepharma, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Opioid Overdose Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Pipeline Therapies, and Treatment Algorithm | Key Companies - Purdue Pharma, Orexo, Quivivepharma, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Opioid Overdose Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Opioid Overdose Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Opioid Overdose Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the Opioid Overdose pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Opioid Overdose collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Opioid Overdose Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/b332819302876471deda93af7793c853.jpg\" alt=\"Opioid Overdose Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Opioid Overdose Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Opioid Overdose<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Opioid Overdose Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Opioid Overdose key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Opioid Overdose Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the<strong> Opioid Overdose market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Opioid Overdose Therapeutics Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The dynamics of the Opioid Overdose market is anticipated to change in the coming years owing to the rise in healthcare spending across the world.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Opioid Overdose market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Purdue Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Orexo<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Quivivepharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adapt Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Indivior Inc.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Opioid Overdose Therapies Covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Revex&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OX124<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">QEV-817<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Narcan<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sublocade<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for sample pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/opioid-overdose-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/opioid-overdose-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Opioid Overdose<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the <strong>Opioid Overdose market<\/strong> is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Overdose Research &amp; Development. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the <strong>Opioid Overdose treatment market<\/strong>. Several potential therapies for Opioid Overdose are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Opioid Overdose market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Opioid Overdose pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/opioid-overdose-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Opioid Overdose Novel Therapies And Emerging Technologies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Opioid Overdose&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Opioid Overdose Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Opioid Overdose &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Opioid Overdose Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Opioid Overdose Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Opioid Overdose Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Opioid Overdose Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Opioid Overdose Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Opioid Overdose Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Opioid Overdose Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Opioid Overdose Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Opioid Overdose Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/opioid-overdose-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/opioid-overdose-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/opioid-overdose-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Opioid Overdose Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Opioid Overdose Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Opioid Overdose market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Trending Healthcare Blog&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Myasthenia Gravis Market Size and Share Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The current treatment for Myasthenia Gravis focuses on immune system regulation and suppression on a broad scale. The therapies are associated with considerable side effects. To fulfil the unmet need, several pharmaceutical companies across the globe, such as Valeant Pharmaceuticals, Astellas Pharma, Viela Bio, UCB, Argenx, Alexion Pharmaceuticals, Grifols, Janssen Pharmaceutical, Roche, and others, are testing their drug candidates with novel MoA that can be used as first-line of therapy or second-line of treatment for the Myasthenia Gravis. Read More:&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/myasthenia-gravis-market\">Myasthenia Gravis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=opioid-overdose-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-purdue-pharma-orexo-quivivepharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=opioid-overdose-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-purdue-pharma-orexo-quivivepharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP Opioid Overdose Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Opioid Overdose Market. The Opioid Overdose Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/opioid-overdose-clinical-and-nonclinical-studies-therapeutic-assessment-emerging-pipeline-therapies-and-treatment-algorithm-key-companies-purdue-pharma-orexo-quivivepharma-and-others_568682.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-568682","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568682"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568682\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}